respiratori
virus
account
season
cold
bronchiol
acut
otiti
sinus
croup
communityacquir
pneumonia
exacerb
chronic
obstruct
pulmonari
diseas
asthma
preval
pandem
orthomyxovirida
influenza
viru
flu
april
estim
approxim
million
case
hospit
death
paramyxovirida
respiratori
syncyti
viru
rsv
infect
result
nearli
two
million
children
requir
medic
care
children
younger
five
year
hospit
annual
one
survey
rsv
preval
pathogen
children
five
year
acut
respiratori
infect
follow
adenovirida
adenoviru
adeno
picornavirida
human
rhinoviru
hrv
initi
effect
pathogen
gene
target
treatment
exert
evolutionari
select
infecti
speci
often
lead
emerg
drug
resist
strain
result
increas
clinic
report
resist
mani
drug
directli
act
viral
protein
dna
particular
resist
differ
class
antivir
drug
becom
clinic
preval
respiratori
viru
infect
seen
rsv
flu
treat
antivir
drug
palivizumab
oseltamivir
respect
pathogen
elucid
two
broad
type
biochem
respons
host
first
activ
host
immun
system
immun
respons
critic
combat
pathogen
infect
overactiv
often
exacerb
tissu
damag
initi
viral
invas
second
respons
upregul
host
gene
protein
biosynthet
pathway
crucial
sustain
pathogen
invas
replic
evas
interestingli
genet
distinct
respiratori
virus
often
modul
common
host
protein
biolog
pathway
infect
exampl
mani
respiratori
virus
trigger
similar
gener
airway
inflammatori
respons
express
cytokin
hugo
gene
name
granulocyt
macrophagecoloni
stimul
factor
inflammatori
respons
turn
initi
iga
product
b
cell
differenti
cell
stimul
consequ
diagnosi
specif
viral
infect
difficult
sinc
divers
respiratori
virus
caus
similar
often
indistinguish
patient
symptom
howev
distinct
respiratori
virus
converg
similar
immun
respons
opportun
also
exist
target
host
protein
pathway
potenti
affect
multipl
viral
pathogen
moreov
human
target
might
less
suscept
evolut
drug
resist
due
constraint
viru
find
altern
host
pathway
prolifer
individu
may
experi
coinfect
sequenti
infect
multipl
virus
bacteria
complic
diseas
diagnosi
drug
prescript
decis
furthermor
patient
infect
multipl
pathogen
may
complic
due
drugdrug
interact
cumul
drug
toxic
immun
system
suppress
observ
hiv
mycobacterium
tuberculosi
coinfect
inde
studi
children
five
year
show
pervas
clinic
occurr
coinfect
involv
combin
rsv
hrv
paramyxovirida
parainfluenza
viru
flu
coronavirida
sarscoronaviru
coron
paramyxovirida
metapneumonia
viru
mpneu
parvovirida
human
bocaviru
adeno
therefor
addit
minim
drug
resist
need
new
therapeut
approach
safe
effect
treat
coinfect
multipl
viral
andor
bacteri
pathogen
particularli
strainspecif
diagnost
treatment
unavail
develop
new
antivir
therapeut
requir
greater
understand
global
host
respons
challeng
differ
type
virus
knowledg
may
lead
identif
novel
human
genom
target
share
across
multipl
viral
infect
well
opportun
reposit
exist
drug
treatment
infecti
diseas
sever
recent
studi
gener
multipl
mrna
microarray
gene
express
dataset
deriv
experi
involv
infect
human
celllin
anim
model
one
major
respiratori
virus
systemat
analysi
respiratori
virushuman
host
gene
express
dataset
determin
common
set
gene
pathway
involv
host
respons
viral
infect
among
signific
pathway
identifi
sever
potenti
new
opportun
repurpos
exist
drug
treatment
respiratori
viral
infect
perform
largescal
analysi
publish
mrna
microarray
dataset
studi
involv
wide
rang
respiratori
virus
human
host
infect
model
focus
human
mrna
array
dataset
order
avoid
complic
inher
crossspeci
comparison
order
ensur
consist
experiment
condit
reduc
bias
due
noisi
poor
qualiti
dataset
institut
iter
process
databas
queri
data
filter
common
pathway
analysi
across
publish
human
mrna
dataset
twelv
relev
respiratori
virus
virus
initi
includ
doubl
strand
dna
virus
herpesvirida
human
cytomegaloviru
cmv
adeno
posit
sens
singl
strand
rna
virus
coron
picornavirida
coxsackieviru
cox
hrv
picornavirida
echoviru
echo
picornavirida
enteroviru
entero
neg
sens
singl
strand
rna
virus
flu
mpenu
rsv
bunyavirida
hantaviru
hant
sin
nombr
viru
snv
list
later
narrow
includ
subset
list
tabl
base
filter
process
outlin
materi
method
shown
figur
total
seven
differ
respiratori
virus
analyz
repres
fifteen
uniqu
gene
express
omnibu
geo
dataset
indic
geo
seri
gse
access
number
nine
differ
human
cell
type
seven
differ
array
platform
total
uniqu
comparison
note
one
dataset
contain
two
differ
virus
flu
rsv
analyz
queri
geo
databas
prescreen
obviou
noncandid
dataset
associ
human
array
platform
least
dataset
associ
least
one
twelv
respiratori
virus
howev
consid
condit
geo
dataset
candidaci
least
four
dataset
exclud
one
case
adeno
dataset
pmid
unpublish
less
three
sampl
per
treatment
group
cox
pmid
unpublish
cmv
dataset
anoth
exampl
cmv
dataset
lack
healthycontrol
treatment
group
addit
least
four
dataset
comparison
group
fit
filter
inclus
instanc
hrv
dataset
origin
studi
design
observ
differ
hrv
infect
asthmat
nonasthmat
patient
asthmat
comparison
group
data
elimin
analysi
potenti
difficulti
distinguish
host
inflammatori
respons
due
viral
infect
associ
chronic
asthma
similarli
combin
flu
hrv
rsv
dataset
contain
two
main
patient
group
one
group
classifi
develop
symptom
exposur
singl
viru
studi
group
develop
symptom
exposur
group
develop
symptom
three
virus
consid
analysi
asymptomat
group
omit
total
geo
dataset
repres
uniqu
comparison
differ
time
point
andor
viru
strain
analyz
qualiti
met
four
requir
dataset
candidaci
singl
dataset
exhibit
overal
poor
qualiti
control
qc
therefor
dataset
repres
comparison
group
analyz
differenti
express
howev
qc
analysi
across
candid
dataset
reveal
two
outlier
sampl
two
sampl
one
outlier
dataset
sampl
sampl
sampl
total
seven
sampl
remov
five
differ
dataset
illustr
kernel
densiti
principl
compon
analysi
pca
plot
gener
qc
analysi
shown
figur
rsv
treatment
median
hour
post
infect
rsv
control
baselin
group
addit
qc
analysi
result
includ
median
absolut
deviat
mad
score
plot
pairwis
correl
map
shown
figur
initi
sampl
except
show
accept
kernel
densiti
figur
pca
figur
mad
score
figur
pairwis
correl
figur
plot
sampl
remov
conform
kernel
densiti
sampl
b
fell
outsid
hotel
alpha
threshold
repres
superimpos
ellipt
pca
plot
c
outlier
mad
score
pairwis
correl
plot
second
qc
round
perform
result
nonconform
sampl
discard
subsequ
qc
analysi
gener
accept
result
kernel
densiti
figur
pca
figur
mad
score
figur
pairwis
correl
figur
thu
dataset
pass
criteria
inclus
analysi
dataset
exhibit
accept
qualiti
analyz
probe
differenti
express
exampl
volcano
plot
shown
figur
rsv
treatment
group
peak
symptom
versu
control
group
data
origin
cutoff
level
increas
decreas
probe
express
level
respect
pvalu
use
throughout
repres
red
line
figur
comparison
group
least
differenti
express
probe
although
number
vari
greatli
indic
potenti
fals
discov
probe
exampl
comparison
group
within
differenti
express
probe
comparison
group
within
differenti
express
probe
howev
conserv
pathway
enrich
approach
employ
tend
attenu
fals
discov
gene
three
comparison
group
meet
least
squar
mean
lsm
threshold
requir
exclud
differenti
express
probe
list
two
entero
comparison
group
unpublish
dataset
third
comparison
group
rsv
treatment
lsm
filter
dataset
total
comparison
group
remain
comparison
group
differenti
express
probe
map
correspond
gene
pvalu
assign
pathway
map
use
softwar
genego
access
june
next
comparison
group
signific
pathway
list
combin
find
union
signific
pathway
combin
pathway
list
treatment
group
least
one
signific
pathway
total
approxim
pathway
map
avail
metabas
determin
signific
comparison
group
signific
pathway
total
signific
pathway
comparison
group
contain
less
signific
pathway
lead
exclus
eleven
comparison
group
union
list
exclud
group
hrv
hour
elimin
one
comparison
group
hrv
hour
elimin
one
comparison
group
strain
flu
hour
hour
anoth
strain
hour
elimin
three
comparison
group
rsv
hour
elimin
comparison
group
cmv
hour
elimin
comparison
group
flu
hour
elimin
comparison
group
end
final
step
filter
process
total
dataset
comparison
group
remain
tabl
enrich
pathway
seven
respiratori
virus
repres
least
one
comparison
group
tabl
list
rank
first
viral
frequenc
follow
sum
normal
viral
express
nve
pathway
also
shown
differenti
express
well
total
number
network
object
across
comparison
top
enrich
pathway
list
tabl
along
percentag
name
differenti
express
gene
viral
frequenc
least
five
pathway
top
five
pathway
chosen
analysi
map
pathway
epiderm
growth
factor
receptor
egfr
signal
signal
interferongamma
ifng
signal
histamin
receptor
signal
signal
figur
tabl
addit
parkinubiquitin
proteasom
system
parkinup
pathway
chosen
analysi
previous
associ
innat
immun
might
interest
new
mechan
host
respons
respiratori
viral
infect
figur
nve
differenti
express
gene
frequenc
least
six
virus
shown
tabl
along
associ
pathway
list
rank
greatest
viral
frequenc
number
pathway
gene
differenti
express
nve
valu
gene
along
associ
pathway
rank
greatest
viral
frequenc
follow
number
pathway
gene
differenti
express
tabl
ensur
nve
bia
toward
particular
comparison
group
inde
singl
dataset
contribut
overal
nve
singl
viru
tabl
hierarch
cluster
quantil
normal
fold
chang
valu
gene
express
valu
least
comparison
least
comparison
signific
least
seven
comparison
figur
well
gene
nve
least
six
virus
figur
reveal
domin
cluster
gse
viru
type
consist
upregul
gene
upregul
least
six
virus
downregul
one
viru
nuclear
factor
kappa
light
polypeptid
gene
enhanc
bcell
inhibitor
alpha
nfkbia
tumor
necrosi
factor
alphainduc
protein
chemokin
cc
motif
ligand
interferon
regulatori
factor
prostaglandinendoperoxid
synthas
chemokin
cc
motif
ligand
dual
specif
phosphatas
eukaryot
translat
initi
factor
kinas
tnf
receptor
superfamili
member
fa
suppressor
cytokin
signal
tnf
receptorassoci
factor
ubiquitinconjug
enzym
consist
downregul
mrna
downregul
least
six
virus
upregul
one
viru
sought
drug
repurpos
candid
target
top
five
enrich
pathway
parkinup
pathway
search
drugbank
databas
version
http
wwwdrugbankca
access
august
drug
target
differenti
express
gene
viral
frequenc
least
five
tabl
thirteen
gene
almost
origin
gene
associ
least
one
approv
small
molecul
protein
therapi
gene
prostaglandinendoperoxid
synthas
tnf
matrix
metallopeptidas
jun
protooncogen
jun
interleukin
beta
coagul
factor
iii
regulatori
subunit
intercellular
adhes
molecul
nuclear
factor
kappa
light
polypeptid
gene
enhanc
bcell
caspas
tubulin
beta
select
gene
along
characterist
evalu
potenti
drug
target
involv
immun
respons
jackson
laboratori
knockinknockout
mous
jax
phenotyp
approv
market
small
molecul
drug
protein
therapi
current
indic
drug
list
tabl
note
current
indic
may
gene
target
list
mimosin
gene
target
glucosamin
gene
target
current
indic
interact
natalizumab
gene
target
gallium
nitrat
gene
target
gene
target
unclear
addit
therapi
associ
cyclooxygenas
inhibitor
known
sideeffect
issu
thu
explor
therefor
exclud
tabl
leav
ten
gene
potenti
drug
repurpos
potenti
case
drug
repurpos
discuss
indepth
four
target
tnf
studi
use
systemat
process
minim
potenti
technic
nois
could
arisen
compar
analysi
fifteen
uniqu
dataset
nine
differ
cell
type
seven
differ
array
platform
measur
includ
candid
dataset
filter
follow
qc
differenti
gene
express
pathway
enrich
analys
total
one
third
total
comparison
remov
result
filter
process
indic
conserv
analysi
approach
previous
use
largescal
mergedsam
analys
integr
largescal
microarray
dataset
involv
cancer
tissu
multipl
laboratori
howev
small
sampl
size
dataset
use
present
studi
requir
rigor
methodolog
identifi
data
outlier
knowledg
qc
analysi
perform
geo
dataset
uniqu
studi
although
dataset
complet
disregard
qc
analysi
sampl
clear
outlier
thu
potenti
skew
data
kauffmann
huber
demonstr
improv
signaltonois
ratio
perform
post
normal
qc
analysi
remov
array
outlier
within
experi
author
use
maplot
boxplot
logratio
determin
outlier
instead
mad
score
pca
pairwis
correl
employ
studi
fundament
concept
data
improv
outlier
remov
appli
regardless
qc
analysi
approach
despit
divers
natur
microarray
data
analyz
found
larg
overlap
comparison
group
signific
pathway
especi
immun
system
top
twenti
enrich
pathway
eighteen
associ
immun
respons
tabl
exampl
egfr
signal
known
activ
infect
respiratori
virus
flu
entero
signal
associ
coron
rsv
gener
immun
respons
interferon
gamma
ifng
signal
initi
flu
rsv
interleukin
signal
stimul
flu
compon
gener
immun
respons
interferon
interleukin
pathway
activ
infecti
agent
hepat
c
viru
hcv
hiv
tuberculosi
well
chronic
diseas
like
crohn
diseas
diabet
metastat
melanoma
overal
relationship
transitori
host
immun
respons
launch
pathogen
infect
versu
seen
chronic
autoimmun
neurodegen
diseas
complex
intens
area
investig
addit
consider
subtl
shift
gene
function
role
differ
cell
tissu
type
amongst
variou
diseas
thu
cautiou
linkag
pathway
involv
infect
chronic
diseas
impli
analysi
without
valid
studi
parkin
ligas
associ
progress
neurodegen
disord
parkinson
diseas
central
hub
protein
parkinup
pathway
ubiquin
protein
encod
septin
tubulin
alpha
beta
glycosyl
form
synuclein
alpha
snca
degrad
proteasom
also
ubiquin
synuclein
alpha
interact
protein
sncaip
regul
snca
interact
homolog
ubox
contain
protein
ubiquitin
protein
ligas
enhanc
ubiquitin
g
proteincoupl
receptor
associ
fbox
wd
repeat
domain
contain
cullin
ubiquitin
cyclin
e
deactiv
protolyt
cleavag
caspas
casp
activ
either
heat
shock
protein
parkinup
pathway
commonli
associ
gener
immun
respons
viral
infect
howev
ubiquityl
protein
known
play
role
host
defens
associ
influenza
infect
neuroinflamm
earli
onset
autosom
recess
parkinson
diseas
recent
suggest
least
one
factor
progress
parkinson
diseas
format
neuotox
lewi
bodi
due
increas
snca
increas
snca
believ
result
lossoffunct
mutat
caus
disrupt
protein
local
solubl
polymorph
gene
also
associ
suscept
infecti
diseas
leprosi
typhoid
fever
paratyphoid
fever
although
exact
mechan
still
unclear
jang
et
al
observ
activ
snca
mous
nervou
tissu
long
pathogen
flu
infect
increas
level
snca
mirror
found
parkinson
diseas
similarli
recent
find
rohn
catlin
indic
flu
potenti
caus
factor
parkinson
diseas
inde
link
flu
neurodegen
diseas
suggest
includ
seizur
transvers
myeliti
express
aphasia
syncop
enceph
neuromyel
optica
central
nervou
system
diseas
gener
low
signal
mrna
level
might
due
signific
regul
posttransl
process
studi
need
determin
mechan
virus
modul
parkinup
pathway
infect
normal
bind
nativ
cofactor
vii
viia
induc
blood
coagul
cascad
treatment
recombin
coagul
factor
viia
promot
blood
coagul
hemophiliac
esmon
et
al
suggest
coagul
could
use
therapeut
modul
inflamm
respons
vice
versa
also
caution
danger
increas
incid
thrombosi
consist
upregul
across
five
virus
suggest
immunecoagul
axi
alreadi
initi
supplement
activ
may
caus
thrombosi
complic
studi
need
develop
therapeut
could
balanc
innat
immun
respons
trigger
coagul
factor
viia
therapi
stabil
antithrombot
state
cytokin
involv
inflammatori
respons
cell
prolifer
differenti
apoptosi
specif
cleav
activ
form
proteas
activ
inflammasom
inde
consist
regul
across
cmv
flu
hrv
mpenu
rsv
like
correl
inflammasom
activ
howev
overexpress
caus
multipl
inflammatori
disord
antagonist
neutral
canakinumab
could
potenti
reduc
inflamm
damag
associ
viral
infect
tnf
wide
rang
biolog
function
includ
modul
immun
respons
pathogen
assault
mous
tnf
knockout
phenotyp
includ
abnorm
immun
system
physiolog
increas
suscept
viral
infect
increas
decreas
suscept
bacteri
infect
studi
tnf
mostli
regul
infect
cmv
coron
cox
flu
direct
ambigu
mpneu
express
rsv
total
disrupt
tnf
function
would
deleteri
host
instanc
partial
tnf
inhibit
provid
clinic
benefit
patient
viral
complic
pranlukast
cysteinyl
leukotrien
antagonist
reduc
bronchospasm
caus
allerg
reaction
usual
asthmat
individu
drug
inhibit
tnfalpha
block
macrophag
cysteinyl
leukotrien
receptor
suppress
nfkappa
b
activ
pranlukast
recent
shown
benefici
case
respiratori
syncyti
viru
postbronchiol
also
wide
varieti
diseas
strong
inflammatori
complic
cystic
fibrosi
cancer
atherosclerosi
eosinophil
cystiti
otiti
media
capsular
contractur
eosinophil
gastrointestin
disord
amrinon
type
pyridin
phosphodiesteras
inhibitor
use
treatment
congest
heart
failur
inhibitor
tnf
phosphodiesteras
inhibitor
shown
alter
immun
respons
one
case
specif
tnf
amrinon
known
modul
pro
antiinflammatori
factor
endotoxinstimul
cell
type
phosphodiesteras
inhibitor
use
treat
rsvinduc
airway
hyperrespons
lung
eosinophilia
therefor
indirect
evid
suggest
armiron
may
benefici
respiratori
viral
infect
situat
inhibit
tnf
via
type
phosphodiesteras
although
yet
seen
clinic
studi
encod
matrix
metallopeptidas
degrad
type
iv
v
collagen
implic
arthriti
metastasi
specul
role
play
infect
analysi
find
gene
upregul
three
virus
downregul
two
differ
virus
studi
observ
upregul
exposur
doubl
strand
rna
import
airway
injuri
specif
rsv
express
induc
mention
activ
inflammasom
inhibitor
marimastat
minocyclin
captopril
could
benefici
assum
protein
coopt
infect
viru
tissu
remodel
block
may
also
reduc
inflammatori
damag
downregul
inflammasom
case
parkinup
pathway
inhibit
tubulinbeta
format
may
reduc
viral
prolifer
given
flu
util
acetyl
tubulin
protein
traffick
increas
neuron
class
iii
tubb
occur
cox
infect
inhibitor
minocyclin
could
use
increas
ubiquitinas
activ
turn
decreas
tuba
tubb
avail
mention
compon
inflammasom
activ
precursor
therefor
inhibitor
would
antagonist
relationship
henc
inflammasom
inhibitor
would
agonist
therebi
reduc
accumul
snca
regard
inhibitor
may
prevent
unnecessari
inflammasom
activ
via
may
also
reduc
accumul
neurotox
lewi
bodi
activ
howev
caspas
specif
parkinup
pathway
inhibit
regard
may
result
toxic
complic
addit
mous
jax
phenotyp
show
increas
decreas
suscept
bacteri
infect
well
decreas
inflammatori
respons
inhibit
may
prove
benefici
term
increas
inflammatori
respons
ambigu
term
benefit
bacteri
infect
analysi
express
also
somewhat
variabl
across
viru
type
therefor
studi
need
specif
role
caspas
tubulin
host
respons
respiratori
viru
infect
modul
human
host
pathway
treatment
viral
infect
potenti
drawback
respect
toxic
sideeffect
exampl
although
interferon
wide
use
help
combat
viral
pathogen
treatment
known
caus
array
sideeffect
relat
toxic
includ
confus
lethargi
impair
mental
statu
numb
tingl
fever
chill
headach
anorexia
sepsi
anoth
caveat
protein
benefici
upregul
initi
viral
infect
detriment
effect
overactiv
prolong
period
thu
determin
desir
mechan
direct
therapeut
intervent
requir
care
studi
although
target
hostpathogen
interact
challeng
therapeut
approach
consider
upsid
benefit
respect
overcom
pathogenmedi
drug
resist
capabl
treat
multipl
coinfect
pathogen
studi
suggest
sever
potenti
humanhost
protein
could
target
futur
therapeut
well
possibl
drug
candid
investig
repurpos
respiratori
viru
infect
nation
center
biotechnolog
inform
geo
databas
http
wwwncbinlmnihgovgeo
access
januari
juli
search
human
mrna
dataset
twelv
respiratori
virus
virus
doubl
strand
dna
virus
herpesvirida
human
cytomegaloviru
adenovirida
adenoviru
posit
sens
singl
strand
rna
virus
coronavirida
sarscoronaviru
picornavirida
coxsackieviru
picornavirida
human
rhinoviru
picornavirida
echoviru
picornavirida
enteroviru
neg
sens
singl
strand
rna
virus
orthomyxovirida
influenza
viru
paramyxovirida
metapenumonia
viru
paramyxovirida
respiratori
syncyti
viru
bunyavirida
hantaviru
sin
nombr
viru
subsequ
filter
step
figur
reduc
number
virus
suitabl
dataset
seven
speci
tabl
analyz
geo
dataset
contain
least
one
treatment
group
control
group
treatment
experiment
variabl
studi
usual
viru
type
strain
time
point
group
collect
individu
sampl
replic
origin
microarray
chip
comparison
group
treatment
group
compar
control
group
particular
dataset
may
one
comparison
group
criteria
dataset
inclus
final
analysi
chosen
prior
analysi
dataset
candidaci
filter
consist
four
criteria
dataset
must
contain
least
sampl
per
treatment
control
group
sampl
size
less
would
mean
loss
statist
power
subsequ
analysi
microarray
platform
must
support
either
affymetrix
agil
illumina
due
probe
map
abil
softwar
use
subsequ
analysi
gene
express
profil
deriv
human
cell
probe
use
humanbas
genom
microarray
platform
speci
dataset
must
contain
least
one
wildtyp
infect
treatment
group
ie
unmodifi
viru
strain
infect
mechan
least
one
healthi
control
group
ie
genet
media
modif
gene
knock
out
inhibitor
respect
prior
qualiti
control
qc
analysi
prescreen
preprocess
dataset
normal
raw
data
studi
design
tabl
import
geo
databas
data
assum
normal
robust
multiarray
averag
case
publish
studi
use
altern
normal
method
appropri
intens
valu
transform
variou
experiment
paramet
time
point
viru
strain
number
replic
extract
studi
design
tabl
sampl
irrelev
main
studi
design
mark
segreg
exclus
downstream
analysi
exclud
qualiti
assess
classifi
fail
meet
treatment
specif
candid
filter
step
studi
larg
number
miss
intens
valu
annot
flag
qc
analysi
assess
sampl
dataset
kernel
densiti
pca
mad
pairwis
pearson
correl
kernel
densiti
normal
distribut
pca
valu
within
hotel
alpha
level
threshold
mad
score
score
rang
outlier
innertreat
group
pair
wise
correl
sampl
deriv
singl
cell
taken
individu
donor
figur
creat
use
array
studio
softwar
version
omicsoft
corpor
research
triangl
park
nc
usa
subsequ
analysi
comparison
group
treat
separ
regardless
dataset
origin
order
gain
wider
less
bia
view
repres
gene
pathway
comparison
group
pass
qc
analysi
filter
lsm
valu
calcul
probe
use
array
studio
order
reduc
number
fals
posit
due
low
probe
intens
valu
probe
within
filter
dataset
test
biolog
statist
relev
use
array
studio
implement
fold
chang
statist
model
respect
specif
determin
probe
fold
chang
express
compar
control
geometr
mean
probe
transform
intens
valu
within
treatment
gener
normal
correspond
control
group
geometr
mean
treatment
versu
control
data
fit
gener
linear
model
associ
pvalu
probe
calcul
use
modifi
ttest
thu
consid
differenti
express
probe
within
comparison
group
must
pvalu
gener
linear
model
test
fold
chang
either
direct
visual
comparison
group
signific
fold
chang
volcano
plot
gener
use
array
studio
probe
pvalu
versu
transform
fold
chang
fc
valu
accord
follow
piecewis
function
differenti
express
probe
map
correspond
gene
use
metacoremetabas
genego
softwaredatabas
packag
creat
biolog
pathway
network
gene
list
databas
access
june
one
probe
map
gene
probe
highest
magnitud
fold
chang
valu
use
gene
thu
map
differenti
express
probe
list
becam
differenti
express
gene
list
comparison
group
differenti
express
gene
list
comparison
group
analyz
enrich
pathway
use
genego
pvalu
pathway
map
metabas
gener
comparison
group
use
hypergeometr
test
order
pathway
consid
enrich
comparison
group
must
contain
pathway
pvalu
occur
total
studi
enrich
pathway
list
rank
viral
frequenc
defin
number
virus
repres
least
one
comparison
group
sum
normal
viral
express
nve
enrich
pathway
nve
pathway
calcul
use
number
comparison
contain
signific
pathway
within
viru
type
rel
number
comparison
within
viru
type
exampl
one
four
flu
comparison
pathway
signific
nve
flu
would
rank
pathway
fashion
result
clearer
determin
pathway
share
across
multipl
virus
irrespect
time
strain
type
number
comparison
group
examin
rank
pathway
list
describ
top
five
signific
pathway
addit
pathway
repres
uniqu
mechan
analyz
map
protein
label
accord
number
virus
transcript
differenti
express
thu
yield
viral
frequenc
protein
case
protein
complex
made
subunit
greatest
magnitud
fold
chang
valu
subunit
chosen
repres
entir
complex
genego
use
visual
pathway
map
similar
pathway
nve
nve
gene
within
six
chosen
pathway
calcul
use
number
comparison
contain
either
regul
gene
protein
within
viru
type
rel
number
comparison
within
viru
type
exampl
two
three
rsv
comparison
gene
x
upregul
gene
x
nve
rsv
would
perform
complet
linkag
correl
distanc
hierarch
cluster
use
arraystudio
quantil
normal
fold
chang
valu
determin
separ
qualiti
analyz
data
cluster
perform
gene
express
valu
least
total
number
comparison
use
matlab
function
knnimput
imput
miss
fold
chang
valu
use
knearest
neighbor
estim
matlab
version
mathwork
cambridg
approv
market
small
molecul
protein
therapeut
differenti
express
protein
modul
respiratori
virus
obtain
drugbank
databas
version
http
wwwdrugbankca
access
august
consid
drug
launch
product
experiment
clinic
evid
direct
interact
gene
product
question
therapi
interact
target
approv
indic
identifi
use
combin
drugbank
drug
manufactur
inform
page
nation
center
biotechnolog
inform
pubchem
http
pubchemncbinlmnihgov
access
septemb
gene
http
wwwncbinlmnihgovgen
access
septemb
databas
supplement
evid
mechan
action
obtain
immun
infectionrel
jackson
laboratori
knockinknockout
mous
jax
phenotyp
http
wwwjaxorg
access
septemb
